SU086

SU086 is a novel chalcone derivative developed as a glycolytic inhibitor for the treatment of aggressive prostate cancer. Identified by researchers at Stanford University, SU086 impairs the glycolytic pathway, which is a critical metabolic route for the growth and survival of cancer cells. Preclinical studies have demonstrated that SU086 inhibits prostate cancer cell growth, migration, and invasion in vitro. Furthermore, it has shown significant efficacy in delaying tumor growth in cell line-derived xenograft models of castration-resistant prostate cancer (CRPC) and patient-derived xenografts (PDXs) in vivo. SU086 is effective against both androgen receptor (AR)-sensitive and AR-insensitive prostate cancers and has demonstrated strong synergistic effects when combined with standard-of-care second-generation anti-androgens, such as enzalutamide and abiraterone.